Letter to the Editor

Comparison of symptomatic and asymptomatic infections due to severe acute respiratory coronavirus virus 2 (SARS-CoV-2) in San Francisco long-term care facilities

Janice K. Louie MD, MPH1-2, Juliet E. Stoltey MD, MPH1-2, Hyman M. Scott MD, MPH1-2, Stephanie Trammell MPH1, Ejovwoke Ememu PhD1, Michael C. Samuel DrPH2, Tomas J. Aragon MD, DrPH1,3 and Godfred Masinde PhD, MBA1

1San Francisco Department of Public Health, San Francisco, California, 2University of California, San Francisco, San Francisco, California and 3University of California, Berkeley, Berkeley, California

To the Editor—Severe acute respiratory coronavirus virus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19) infection, has contributed to substantial mortality in older populations in long-term care facilities (LTCFs). With high prevalence of asymptomatic infection reported in both healthcare workers (HCWs) and residents, efforts to prevent the introduction and transmission of COVID-19 in these high-risk settings has led to costly resource and labor-intensive national recommendations.1-3

Accordingly, in March 2020 the San Francisco Department of Public Health implemented stringent recommendations in skilled nursing facilities (SNFs) and assisted living facilities (ALFs) according to Centers for Disease Control and Prevention COVID-19 recommendations.4 These included restrictions of visitors and communal activities, rigorous infection control practices, universal masking, and enhanced surveillance for and testing of suspect cases. From March 12 to May 15, 2020, the suspect case definition included fever (≥37.8°C), cough, or shortness of breath. After May 15, additional symptoms included fatigue, myalgias, headache, new loss of taste or smell, sore throat, congestion, nausea, vomiting, diarrhea or altered mental status. Once COVID-19 cases were identified, outbreak response included contact investigation and facility-wide testing, cohorting of infected from noninfected residents, and home isolation of infected HCWs. On May 7, periodic facility-wide surveillance testing regardless of presence of symptoms was implemented in SNFs.

Laboratory testing with reverse-transcription polymerase chain reaction (RT-PCR) was performed at either hospital or commercial laboratories or the San Francisco Public Health Laboratory (SFPHL). Persons with absence of the aforementioned symptoms at time of specimen collection were defined as asymptomatic. We used the Mann-Whitney U test to compare the cycle threshold (Ct) values of symptomatic and asymptomatic persons, and the Pearson correlation coefficient to measure the association between Ct values and age.

Results

From March 30 to June 15, 2020, we identified 5 COVID-19 outbreaks in 4 SNFs and 1 elderly ALF. In total, 543 persons were tested and 184 (33.9%) were SARS-CoV-2 positive (Table 1). Of these 184 SARS-CoV-2–positive persons, 63 (34.2%) were symptomatic (including 31 HCWS and 32 residents) and 121 (65.7%) were asymptomatic (including 45 HCWs and 76 residents). The median age for a COVID-19-infected person was 71.0 years (range, 21–99).

No COVID-19–infected HCWs were hospitalized or died. Of 107 COVID-19–infected residents with available information, 30 (28%) were hospitalized (including 24 symptomatic and 6 asymptomatic residents) and 14 (13.0%) died (including 10 symptomatic residents and 4 without documented symptoms prior to being found unconscious).

Of 184 persons with positive SARS-CoV-2 tests, 106 (57.6%) were tested at the SFPHL; 11 (10.4%) were symptomatic (including 3 HCWs and 8 residents); and 95 (89.6%) were asymptomatic (including 30 HCWs and 65 residents). The overall median Ct value was 16.4 (range, 3.0–29.7). The median Ct values for symptomatic and asymptomatic persons were 11.5 (range, 3.0–29.7) and 16.7 (range, 3.3–29.7), respectively. There was no significant difference when comparing the median Ct values of symptomatic and asymptomatic persons, and no significant correlation between Ct value and age (Pearson correlation coefficient -0.06; 95% confidence interval [CI], −0.25 to 0.13; P > .05).

Discussion

Mass testing in LTCFs revealed that >65% of SARS-CoV-2–infected HCWs and residents were asymptomatic. Cycle threshold values, which may be an indirect proxy for viral load, were comparable in both asymptomatic and symptomatic populations.5 Although the high prevalence of asymptomatic infection in LTCFs has been well documented, descriptions of associated Ct values are limited. In 2 SNF outbreaks in Washington where...
and both symptom-based and periodic surveillance facility-wide transmission and COVID-19 in high-risk LTCF settings are recommendations for surveillance and management of SARS-CoV-2 infection. Our findings emphasize that current extensive rectored for fever or respiratory symptoms but did not systematically

ment testing of mostly adults in England, identified no significant difference in Ct values in asymptomatic compared to symptomatic populations.7–9 These findings support biologic plausibility for the potential of high risk of asymptomatic transmission.

Similar to others, in our study, a larger proportion of symptomatic SARS-CoV-2–infected LTCF residents required hospitalization or died compared to their asymptomatic counterparts.1,2,4 Using symptoms to ascertain SARS-CoV-2 infection in older adults can be challenging, especially in those with dementia who may present atypically.10 SARS-CoV-2–infected LTCF residents should be closely monitored for development of new or acute worsening of chronic symptoms, which may portend a high risk for clinical deterioration and death.

This study had several limitations. Many more asymptomatic persons were tested at the SFPHL compared to symptomatic HCWs and residents, as symptomatic persons were more likely to be referred to clinics or emergency rooms for clinical assessment and testing. During the early part of surveillance, facilities monitored for fever or respiratory symptoms but did not systematically ask about other symptoms (eg, rhinorrhea or diarrhea); therefore, some cases identified as asymptomatic may have had atypical or nonrespiratory COVID-19 symptoms. The presence of symptoms was ascertained at time of specimen collection. Although LTCFs were instructed to report any new symptoms in SARS-CoV-2–infected persons after specimen collection, some symptomatic infections may have been missed, although this is thought to be a small number.

In summary, in this study, a large proportion of LTCF HCWs and residents had asymptomatic COVID-19 infection, and Ct values suggested levels of viral shedding comparable to those with symptomatic infection. Our findings emphasize that current extensive recommendations for surveillance and management of SARS-CoV-2 transmission and COVID-19 in high-risk LTCF settings are warranted, including rigorous employment of isolation and infection control measures, universal use of personal protective equipment, and both symptom-based and periodic surveillance facility-wide testing to identify both symptomatic and asymptomatic infected persons.

Acknowledgments. We thank Robin Allen-Contreras, Sabrina Alonso, Anna Chodos, Nicole Copeland, Amie Dubois, George Lee, Kaylene Lemen, Wendy Lu, Melissa Ongpin, Natalya Sturtz, Lisa Watson, and Sheilah Zarate at the San Francisco Department of Public Health, and the laboratorians at the San Francisco Public Health Laboratory, for their dedication to conducting active surveillance, testing, and ensuring the health and safety of San Francisco LTCF residents. We are grateful to Howard Tokunaga, PhD, San Jose State University, and Cathleen Xing, PhD, San Francisco Department of Public Health, for their assistance with statistical methodology.

Financial support. No financial support was provided relevant to this article.

Conflicts of interest. All authors report no conflicts of interest relevant to this article.

References

1. Arons MM, Hatfield KM, Reddy SC, et al. Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility. N Engl J Med 2020;382:2081–2090.
2. Kimball A, Hatfield KM, Arons M, et al. Asymptomatic and presymptomatic SARS-CoV-2 infections in residents of a long-term care skilled nursing facility—King County, Washington, March 2020. Morb Mortal Wkly Rep 2020;69:377–381.
3. Sanchez GV, Biedron C, Fink JR, et al. Initial and repeated point prevalence surveys to inform SARS-CoV-2 infection prevention in 26 skilled nursing facilities—Detroit, Michigan, March–May 2020. Morb Mortal Wkly Rep 2020;69:882–886.
4. Louie JK, Scott HM, DuBois A, et al. Lessons from mass testing for COVID-19 in long-term care facilities for the elderly in San Francisco. Clin Infect Dis 2020. doi: 10.1093/cid/ciaa1020/5873783.
5. Preparing for COVID-19 in nursing homes. Centers for Disease Control and Prevention website. https://www.cdc.gov/coronavirus/2019-ncov/hcp/long-term-care.html. Published 2020. Accessed November 15, 2020.
6. Moore NM, Li H, Scheibal D, Lindsay J, Hayden MK. Comparison of two commercial molecular tests and a laboratory-developed modification of the CDC 2019-nCoV reverse transcriptase PCR assay for the detection of SARS-CoV-2. J Clin Microbiol 2020;58(8):e00938–20.
7. Seungjae L, Kim T, Lee E, et al. Clinical course and molecular viral shedding among asymptomatic and symptomatic patients with SARS-CoV-2.
infection in a community treatment center in the Republic of Korea. *JAMA Intern Med* 2020;180:1447–1452.

8. Ra SH, Lim JS, Kim G, Kim MJ, Jung J, Kim SH. Upper respiratory viral load in asymptomatic individuals and mildly symptomatic patients with SARS-CoV-2 infection. *Thorax* 2020. doi: 10.1136/thoraxjnl-2020-215042.

9. Singanayagam A, Patel M, Charlett A, *et al.* Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19, England, January to May 2020. *Euro Surveill* 2020;25(32):2001483.

10. Louie JK, Scott HM, Lu W, *et al.* COVID-19–associated deaths in San Francisco: the important role of dementia and atypical presentations in long-term care facilities. *J Gen Intern Med* 2020;35:3413–3415.